ACXP
Acurx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$1.55
-0.04 (-2.52%)
Current Price
| Previous Close | $1.59 |
| Open | $1.60 |
| Day High | $1.61 |
| Day Low | $1.53 |
| Volume | 32,418 |
Stock Information
| Shares Outstanding | 4.30M |
| Cash Equivalents | $9.25M |
| Net Income | $-7.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.66M |
| EPS (TTM) | $-3.79 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-2.59M |
| Income | $-7.50M |
| Book/sh | $2.07 |
| Cash/sh | $2.15 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 3.69 |
| Current Ratio | 3.77 |
Returns & Margins
| ROA | -66.50% |
| ROE | -160.83% |
Ownership
| Insider Ownership | 2.99% |
| Institutional Ownership | 6.17% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.73 |
| P/B | 0.75 |
Analyst Data
| Recommendation | none |
| Target Price | $17.00 |
Technical Indicators
| SMA20 | $1.54 |
| SMA50 | $1.72 |
| SMA200 | $3.16 |
| RSI | 51.24 |
| ATR | 0.1537 |
| Shares Float | 4.17M |
| Short Float | 3.26% |
| Short Ratio | 1.71 |
| Volatility | -2.04 |
| Rel Volume | 0.34 |
Performance History
| Week | +3.33% |
| Month | +0.65% |
| Quarter | -37.75% |
| 6 Months | -43.43% |
| YTD | -43.84% |
| Year | -82.02% |
| 3 Years | -96.60% |
| 5 Years | -98.73% |
| 10 Years | -99.02% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.55 | 32,600 |
| 2026-07-16 | $1.59 | 91,800 |
| 2026-07-15 | $1.75 | 214,600 |
| 2026-07-14 | $1.65 | 130,000 |
| 2026-07-13 | $1.58 | 106,200 |
| 2026-07-10 | $1.50 | 89,700 |
| 2026-07-09 | $1.46 | 69,600 |
| 2026-07-08 | $1.36 | 152,700 |
| 2026-07-07 | $1.45 | 183,900 |
| 2026-07-06 | $1.58 | 94,400 |
| 2026-07-02 | $1.60 | 59,100 |
| 2026-07-01 | $1.53 | 63,300 |
| 2026-06-30 | $1.55 | 96,100 |
| 2026-06-29 | $1.68 | 162,700 |
| 2026-06-26 | $1.52 | 44,700 |
| 2026-06-25 | $1.42 | 53,900 |
| 2026-06-24 | $1.47 | 43,200 |
| 2026-06-23 | $1.42 | 94,400 |
| 2026-06-22 | $1.51 | 80,800 |
| 2026-06-18 | $1.54 | 62,800 |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
đ° Latest News
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Zacks âĸ 2026-06-08T16:00:02Z
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-12T17:05:41Z
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-04-02T13:40:03Z
Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...
GuruFocus.com âĸ 2026-03-24T01:00:31ZCan Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
Zacks âĸ 2026-03-19T13:55:02Z
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-03-17T13:40:04Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-03-11T14:30:34ZAcurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors
Insider Monkey âĸ 2026-02-24T18:12:07Z
Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term
Simply Wall St. âĸ 2026-01-21T12:28:16Z
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-01-06T14:40:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,091,983 | $14,123,227 | $14,577,768 | $12,092,776 |
| Net Non Operating Interest Income Expense | $125,445 | $20,124 | - | - |
| Operating Expense | $8,091,983 | $14,123,227 | $14,577,768 | $12,092,776 |
| General And Administrative Expense | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Interest Income | $125,445 | $20,124 | - | - |
| Interest Income | $125,445 | $20,124 | - | - |
| Normalized Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income From Continuing And Discontinued Operation | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Common Stockholders | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Including Noncontrolling Interests | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Continuous Operations | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Pretax Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Interest Income Non Operating | $125,445 | $20,124 | - | - |
| Operating Income | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-5.32 | $-17.45 | $-23.00 | $-22.40 |
| Basic EPS | $-5.32 | $-17.45 | $-23.00 | $-22.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| EBITDA (Bullshit earnings) | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| EBIT | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| Diluted Average Shares | $1,498,793 | $808,168 | $633,578 | $540,820 |
| Basic Average Shares | $1,498,793 | $808,168 | $633,578 | $540,820 |
| Diluted NI Availto Com Stockholders | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Research And Development | $1,834,506 | $5,403,836 | $6,043,597 | $4,754,271 |
| Selling General And Administration | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Other Gand A | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Assets | $7,689,535 | $3,857,963 | $7,709,123 | $9,376,706 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $7,689,535 | $3,857,963 | $7,709,123 | $9,376,706 |
| Prepaid Assets | $85,018 | $100,123 | $105,776 | $264,955 |
| Receivables | $48,417 | $51,127 | $129,159 | $0 |
| Other Receivables | $48,417 | $51,127 | $129,159 | - |
| Cash Cash Equivalents And Short Term Investments | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Cash And Cash Equivalents | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Cash Financial | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,420,943 | $3,242,842 | $3,042,438 | $2,061,685 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $2,420,943 | $3,242,842 | $3,042,438 | $2,061,685 |
| Payables And Accrued Expenses | $2,381,932 | $2,705,212 | $2,326,131 | $1,518,790 |
| Payables | $6,802 | $4,787 | $3,809 | $29,539 |
| Other Payable | $6,802 | $4,787 | $3,809 | $29,539 |
| Equity | ||||
| Common Stock Equity | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Equity Gross Minority Interest | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Stockholders Equity | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Retained Earnings | $-75,288,494 | $-67,321,956 | $-53,218,853 | $-38,641,085 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $-38,641,085 |
| Other Equity Adjustments | - | - | - | $-38,641,085 |
| Other | ||||
| Ordinary Shares Number | $2,348,113 | $851,534 | $723,411 | $581,380 |
| Share Issued | $2,348,113 | $851,534 | $723,411 | $581,380 |
| Tangible Book Value | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Invested Capital | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Working Capital | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Capitalization | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Additional Paid In Capital | $80,554,738 | $67,936,225 | $57,871,070 | $45,944,478 |
| Capital Stock | $2,348 | $852 | $14,468 | $11,628 |
| Common Stock | $2,348 | $852 | $14,468 | $11,628 |
| Pensionand Other Post Retirement Benefit Plans Current | $39,011 | $537,630 | $716,307 | $542,895 |
| Current Accrued Expenses | $2,375,130 | $2,700,425 | $2,322,322 | $1,489,251 |
| Treasury Shares Number | - | - | $0 | - |
| Total Partnership Capital | - | - | $-53,218,853 | $-38,641,085 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Cash Flow From Continuing Operating Activities | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Operating Gains Losses | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,040 | $0 | - | - |
| Issuance Of Capital Stock | $6,797,112 | $6,405,757 | $5,944,250 | $3,695,182 |
| Financing Cash Flow | $10,637,169 | $6,615,956 | $8,163,322 | $3,695,195 |
| Cash Flow From Continuing Financing Activities | $10,637,169 | $6,615,956 | $8,163,322 | $3,695,195 |
| Net Common Stock Issuance | $6,796,072 | $6,405,757 | $5,944,250 | $3,695,182 |
| Common Stock Issuance | $6,797,112 | $6,405,757 | $5,944,250 | $3,695,182 |
| Other | ||||
| End Cash Position | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Beginning Cash Position | $3,706,713 | $7,474,188 | $9,111,751 | $12,958,846 |
| Changes In Cash | $3,849,387 | $-3,767,475 | $-1,637,563 | $-3,847,095 |
| Proceeds From Stock Option Exercised | $3,841,097 | $210,199 | $2,219,072 | $13 |
| Common Stock Payments | $-1,040 | $0 | - | - |
| Change In Working Capital | $-390,964 | $284,089 | $1,010,773 | $1,248,125 |
| Change In Payables And Accrued Expense | $-408,779 | $200,404 | $980,753 | $1,217,776 |
| Change In Prepaid Assets | $15,105 | $5,653 | $159,179 | $30,349 |
| Change In Receivables | $2,710 | $78,032 | $-129,159 | $0 |
| Stock Based Compensation | $1,569,720 | $3,435,583 | $3,766,110 | $3,302,361 |
| Net Income From Continuing Operations | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Other Non Cash Items | - | - | $559,583 | $430,680 |
| Pension And Employee Benefit Expense | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-25